AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PRO MEDICUS LTD

205.330

-1.840-0.89%

Volume:191.76K

Turnover:39.38M

Market Cap:21.45B

PE:218.57

High:206.940

Open:203.350

Low:201.510

Close:207.170

Loading ...

Overview Company News Filings

Down 20% to 40%: These oversold ASX shares could be bargains hiding in plain sight

Is Weakness In Pro Medicus Limited (ASX:PME) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Simply Wall St.

Now could be a golden opportunity to buy these ASX 200 growth shares

How to build the perfect ASX share portfolio

3 of the best ASX 200 healthcare shares to bring your portfolio to life

Shareholders May Not Overlook Pro Medicus Insiders Selling AU$514m In Stock

Simply Wall St.

Pro Medicus inks R&D agreement with UCSF for Visage AI Accelerator

The Market Herald

Pro Medicus Unit Signs Multi-Year Research Collaboration Agreement for AI Accelerator Platform

MT Newswires Live

BRIEF-Pro Medicus Signs Multi-Year Research Collaboration Agreement With UCSF

Pro Medicus shares rise on big AI news

Pro Medicus Ltd - Pme Signs Multi-Year Research Collaboration Agreement With Ucsf

THOMSON REUTERS

Pro Medicus - Deal for Collaboration on Development and Commercialisation Leveraging Visage AI Accelerator Platform

THOMSON REUTERS

Here are the top 10 ASX 200 shares today

5 'particularly interesting' ASX All Ords stocks to buy amid the Trump tariff mayhem

Beginner investor? Here's how I'd invest $1,000 in ASX shares

Why this fund manager is all in on Pro Medicus shares and recently increased his bet

How dollar cost averaging can reduce stress in a volatile market

What I'd buy before the ASX rebounds: 3 high-conviction share picks

Market Chatter: Pro Medicus Upgraded to "Overweight" by Barrenjoey, Reports Australian Financial Review

MT Newswires Live

Market selloff creates rare buying window: 3 quality ASX 200 shares I'd buy right now

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PME.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PME.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PME.AU\",,,,,undefined,":{"symbol":"PME.AU","market":"AU","secType":"STK","nameCN":"PRO MEDICUS LTD","latestPrice":205.33,"timestamp":1745302320000,"preClose":207.17,"halted":0,"volume":191761,"delay":0,"nameEN":"PRO MEDICUS LTD","floatShares":52960584,"shares":104462909,"eps":0.939404,"marketStatus":"Closed","change":-1.84,"latestTime":"04-22 16:12:00 AEST","open":203.35,"high":206.94,"low":201.51,"amount":39377686,"amplitude":0.02621,"askPrice":205.33,"askSize":166,"bidPrice":205,"bidSize":150,"shortable":3,"etf":0,"ttmEps":0.939404,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":207.17,"dividendRate":0.002289,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":0.892784,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PME.AU\",,,,,undefined,":{"symbol":"PME.AU","floatShares":52960584,"roa":"32.90%","roe":"51.53%","lyrEps":0.792737,"volumeRatio":0.892784,"shares":104462909,"dividePrice":0.47,"high":206.94,"amplitude":0.02621,"preClose":207.17,"low":201.51,"week52Low":99.614,"pbRate":"96.51","psRate":"116.21","week52High":298.706,"institutionHeld":0,"latestPrice":205.33,"committee":-0.050633,"eps":0.939404,"divideRate":0.002289,"volume":191761,"delay":0,"ttmEps":0.939404,"open":203.35,"prevYearClose":249.891,"prevWeekClose":207.17,"prevMonthClose":199.79,"prevQuarterClose":199.79,"fiveDayClose":202.6,"twentyDayClose":223.58,"sixtyDayClose":269.993},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PME.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529936293","title":"Down 20% to 40%: These oversold ASX shares could be bargains hiding in plain sight","url":"https://stock-news.laohu8.com/highlight/detail?id=2529936293","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529936293?lang=en_us&edition=fundamental","pubTime":"2025-04-22 09:05","pubTimestamp":1745283953,"startTime":"0","endTime":"0","summary":"The market has taken a beating in recent weeks, and while some of the selling may be justified, there are always a few high-quality ASX shares that get unfairly dragged down with the rest. These are t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/22/down-20-to-40-these-oversold-asx-shares-could-be-bargains-hiding-in-plain-sight/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU0225283273.USD","LU2133065610.SGD","BK4588","LU1720051017.SGD","BK4127","IE00BZ1G4Q59.USD","LOV.AU","LU0106831901.USD","LU2023251221.USD","LU2028103732.USD","LU0795875086.SGD","BK7021","BK4585","BK7128","LU2089284900.SGD","LU0106261372.USD","BK7094","LU1720051108.HKD","LU1668664300.SGD","LU1548497426.USD","PME.AU","LU2271345857.HKD","LU0912757837.SGD","UNI.AU","LU1989772840.SGD","BK4581","LU1162221912.USD","LU2089283258.USD","LU1989772923.USD","LU2357305700.SGD","LU0795875169.SGD","LU2111349929.HKD","LU0158827948.USD","LU0098860793.USD","BK4534","LU1074936037.SGD","LU0971096721.USD","LU0314104364.USD","LU0006306889.USD","LU1732799900.SGD","IE00BKVL7J92.USD","LU0267386448.USD","LU0320765646.SGD","LU1363072403.SGD","LU1732800096.USD","LU2347655156.SGD","BK4504","LU0158827781.USD","BK4516"],"gpt_icon":0},{"id":"2529084179","title":"Is Weakness In Pro Medicus Limited (ASX:PME) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?","url":"https://stock-news.laohu8.com/highlight/detail?id=2529084179","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529084179?lang=en_us&edition=fundamental","pubTime":"2025-04-21 13:58","pubTimestamp":1745215101,"startTime":"0","endTime":"0","summary":"It is hard to get excited after looking at Pro Medicus'  recent performance, when its stock has declined 21% over the past three months. However, stock prices are usually driven by a company’s financial performance over the long term, which in this case looks quite promising. In this article, we decided to focus on Pro Medicus'  ROE.Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. Simply put, it is used to assess the profitability of a company in relation to its equity capital.  We check all companies for important risks. See what we found for Pro Medicus in our. Return on Equity = Net Profit  ÷ Shareholders' Equity. So, based on the above formula, the ROE for Pro Medicus is:. The 'return' is the profit over the last twelve months. So, this means that for every A$1 of its shareholder's investments, the company generates a profit of A$0.44.Besides, Pro Medicus has been paying dividends for at least ten yea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/weakness-pro-medicus-limited-asx-055821535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["PME.AU","BK7094","BK4212","PME"],"gpt_icon":0},{"id":"2528031158","title":"Now could be a golden opportunity to buy these ASX 200 growth shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2528031158","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528031158?lang=en_us&edition=fundamental","pubTime":"2025-04-18 08:44","pubTimestamp":1744937054,"startTime":"0","endTime":"0","summary":"Market volatility may have shaken confidence in recent weeks, but if you're focused on the long term, this could be a golden opportunity to back high-quality businesses with strong growth potential. But which ASX 200 growth shares?A couple that have been attracting bullish calls from top brokers — and offering compelling upside for patient investors, are listed below. Here's why they could be top picks right now: Life360 Inc  Goldman Sachs is feeling bullish about Life360, the location technology company behind one of the most widely used family safety apps in the world. With approximately 80 million users globally, the broker believes the company is sitting on a huge untapped monetisation opportunity. It currently has a buy rating on the ASX 200 growth share with a $27.00 price target. Based on its current share price of $19.70, this implies potential upside of 37% for investors over the next 12 months. What's driving that conviction?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/18/now-could-be-a-golden-opportunity-to-buy-these-asx-200-growth-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["TAM.AU","BK7104","360.AU","BK7094","LIF","PME.AU","BK4023","BK4613","BK7016"],"gpt_icon":0},{"id":"2528020777","title":"How to build the perfect ASX share portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2528020777","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528020777?lang=en_us&edition=fundamental","pubTime":"2025-04-18 07:08","pubTimestamp":1744931280,"startTime":"0","endTime":"0","summary":"Building a strong ASX share portfolio is one of the best ways to grow long-term wealth. But what does a perfect portfolio look like?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/18/how-to-build-the-perfect-asx-share-portfolio/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["WTC.AU","BK7153","MQG.AU","BK7501","IVV.AU","BK7155","BK7046","WES.AU","BK7067","BK7508","BK7099","BK7016","BK7041","BK7503","XRO.AU","BK7510","BK7511","PME.AU","BK7094","GMG.AU","NDQ.AU","CSL.AU"],"gpt_icon":1},{"id":"2527447668","title":"3 of the best ASX 200 healthcare shares to bring your portfolio to life","url":"https://stock-news.laohu8.com/highlight/detail?id=2527447668","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527447668?lang=en_us&edition=fundamental","pubTime":"2025-04-16 02:00","pubTimestamp":1744740000,"startTime":"0","endTime":"0","summary":"If your portfolio needs a health check, then the healthcare sector could be just what the doctor ordered. ASX 200 healthcare shares have a history of delivering strong, long-term returns thanks to con","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/16/3-of-the-best-asx-200-healthcare-shares-to-bring-your-portfolio-to-life/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU2471134523.USD","LU2471134952.CNY","LU2471134796.USD","LU1868836914.USD","BK7508","BK4552","IE0002270589.USD","BK7067","IE00BFXG1179.USD","IE0004091025.USD","RMD.AU","LU0048573561.USD","LU2237443622.USD","LU2750360997.AUD","LU2237443978.SGD","BK4127","BK4516","BK7501","PME.AU","BK7094","LU1791807156.HKD","LU1868836757.USD","LU2750360641.GBP","LU1868837136.USD","LU0742534661.SGD","BK7007","LU2471134879.HKD","BK4550","LU0061475181.USD","BK7511","LU2237443549.SGD","IE00B19Z3581.USD","LU2237443895.HKD","CSL.AU","IE00B19Z3B42.SGD","BK4585","LU1868836591.USD","LU1868837300.USD","BK4533","LU2237443465.HKD","IE0034235188.USD","LU2237438978.USD","BK4504","LU0251142724.SGD","BK4588","LU0106831901.USD","IE00BSNM7G36.USD","LU1668664300.SGD","IE0004086264.USD","LU2237443382.USD"],"gpt_icon":0},{"id":"2527414054","title":"Shareholders May Not Overlook Pro Medicus Insiders Selling AU$514m In Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2527414054","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527414054?lang=en_us&edition=fundamental","pubTime":"2025-04-15 13:51","pubTimestamp":1744696273,"startTime":"0","endTime":"0","summary":"Last week, Pro Medicus Limited's (ASX:PME) stock jumped 20%, but insiders who sold AU$514m worth of stock in over the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-pme/pro-medicus-shares/news/shareholders-may-not-overlook-pro-medicus-insiders-selling-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7094","PME.AU"],"gpt_icon":0},{"id":"2527439482","title":"Pro Medicus inks R&D agreement with UCSF for Visage AI Accelerator","url":"https://stock-news.laohu8.com/highlight/detail?id=2527439482","media":"The Market Herald","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527439482?lang=en_us&edition=fundamental","pubTime":"2025-04-15 12:17","pubTimestamp":1744690620,"startTime":"0","endTime":"0","summary":"Pro Medicus  is strengthening its investment in research and development for imaging product, the Visage AI Accelerator platform in the U.S., signing a multi-year agreement with the University of California San Francisco.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.The agreement – signed between the university and Pro Medicus’ U.S. subsidiary Visage Imaging, Inc. – will provide a framework through which the two parties will collaborate on the development and commercialisation of the platform, looking specifically into its artificial intelligence capabilities.It will also build on a relationship already established with UCSF through an existing agreement related to Pro Medicus’ Visage 7 Viewer product.Visage Imaging Global CTO Malte Westerhoff said the partnership around Visage AI Accelerator was a very important milestone.“Our AI Accelerator program was designed to closely align ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/pro-medicus-inks-rd-agreement-with-ucsf-for-visage-ai-accelerator-2025-04-15/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["PME.AU","BK7094"],"gpt_icon":0},{"id":"2527102158","title":"Pro Medicus Unit Signs Multi-Year Research Collaboration Agreement for AI Accelerator Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2527102158","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527102158?lang=en_us&edition=fundamental","pubTime":"2025-04-15 10:48","pubTimestamp":1744685302,"startTime":"0","endTime":"0","summary":"Pro Medicus  said that its wholly-owned US unit, Visage Imaging, signed a multi-year research collaboration agreement with the University of California San Francisco as a framework for collaboration to facilitate the development and commercialization leveraging the Visage AI Accelerator platform, according to a Tuesday Australian bourse filing.The agreement has the potential to develop artificial intelligence products to meet clinical goals and ultimately lead to better patient outcomes, Malte Westerhoff, Visage Imaging's global chief technology officer, said.The research collaboration builds on the existing UCSF Visage 7 Viewer agreement.Pro Medicus' shares fell past 1% in recent trading on Tuesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7094","PME.AU"],"gpt_icon":0},{"id":"2527773691","title":"BRIEF-Pro Medicus Signs Multi-Year Research Collaboration Agreement With UCSF","url":"https://stock-news.laohu8.com/highlight/detail?id=2527773691","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527773691?lang=en_us&edition=fundamental","pubTime":"2025-04-15 09:26","pubTimestamp":1744680387,"startTime":"0","endTime":"0","summary":"BRIEF-Pro Medicus Signs Multi-Year Research Collaboration Agreement With UCSFApril 15  - Pro Medicus Ltd PME.AX:DEAL FOR COLLABORATION ON DEVELOPMENT AND COMMERCIALISATION LEVERAGING VISAGE AI ACCELERATOR PLATFORMPME SIGNS MULTI-YEAR RESEARCH COLLABORATION AGREEMENT WITH UCSFFurther company coverage: PME.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QS1Z7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PME.AU","BK7094"],"gpt_icon":0},{"id":"2527448711","title":"Pro Medicus shares rise on big AI news","url":"https://stock-news.laohu8.com/highlight/detail?id=2527448711","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527448711?lang=en_us&edition=fundamental","pubTime":"2025-04-15 09:17","pubTimestamp":1744679850,"startTime":"0","endTime":"0","summary":"Pro Medicus Ltd  shares are on the move on Tuesday after the company made a new announcement. At the time of writing, the health imaging technology company's shares are up slightly to $213.50. Why are Pro Medicus shares rising?Investors have been buying the company's shares after it entered into a multi-year research collaboration agreement with the University of California, San Francisco  — one of the most prestigious academic medical centres in the world. The goal?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/15/pro-medicus-shares-rise-on-big-ai-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7094","PME.AU"],"gpt_icon":0},{"id":"2527750141","title":"Pro Medicus Ltd - Pme Signs Multi-Year Research Collaboration Agreement With Ucsf","url":"https://stock-news.laohu8.com/highlight/detail?id=2527750141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527750141?lang=en_us&edition=fundamental","pubTime":"2025-04-15 08:31","pubTimestamp":1744677080,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QS1Z7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7094","PME.AU"],"gpt_icon":0},{"id":"2527175012","title":"Pro Medicus -  Deal for Collaboration on Development and Commercialisation Leveraging Visage AI Accelerator Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2527175012","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527175012?lang=en_us&edition=fundamental","pubTime":"2025-04-15 08:31","pubTimestamp":1744677080,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QS1Z7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PME.AU","BK7094"],"gpt_icon":0},{"id":"2527186297","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2527186297","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527186297?lang=en_us&edition=fundamental","pubTime":"2025-04-14 15:01","pubTimestamp":1744614107,"startTime":"0","endTime":"0","summary":"It was a flying start to the trading week for the S&P/ASX 200 Index (ASX: XJO) this Monday. After a rough end to last week, investors came back from the weekend with a spring in their steps. By the ti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/14/here-are-the-top-10-asx-200-shares-today-14-april-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["SMR.AU","BK7067","XJO.AU","BK7504","PME.AU","NEU.AU","PNV.AU","BK7501","BK7129","BK7016","WHC.AU","BK7507","CU6.AU","SDR.AU","BK7083","MSB.AU","BK7096","BK7126","BK7094","BK7062","PNI.AU","BK7095","BK7508","MIN.AU"],"gpt_icon":0},{"id":"2527511133","title":"5 'particularly interesting' ASX All Ords stocks to buy amid the Trump tariff mayhem","url":"https://stock-news.laohu8.com/highlight/detail?id=2527511133","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527511133?lang=en_us&edition=fundamental","pubTime":"2025-04-14 13:12","pubTimestamp":1744607549,"startTime":"0","endTime":"0","summary":"The All Ordinaries Index  is up a welcome 1.38% on Monday, but most ASX All Ords stocks remain well down from the market highs on 14 February. Indeed, the All Ords is still down 9.78% since notching its record closing high on the day. The headwinds that have dragged on global and Aussie stock markets alike since then can largely be pinned on the unpredictable and oft-changing trade policies under United States President Donald Trump. Trump's sweeping global tariffs, in particular, have unsettled investors. This, in turn, sent many ASX All Ords stocks tumbling despite no likely fundamental changes to their long-term prospects. \"We, like almost every other investor on the planet, underestimated Trump's resolve to reshape global trade and just how far he appears willing to go to do this,\" said Jun Bei Liu, founder and lead portfolio manager at Ten Cap . Liu pointed to Trump's 2 April 'Liberation Day' tariff announcement as having \"drastically changed the course of the macroeconomic and in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/14/5-particularly-interesting-asx-all-ords-stocks-to-buy-amid-the-trump-tariff-mayhem/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["FPH.AU","BK7501","BK7016","BK7002","REA.AU","COH.AU","PME.AU","BK7094","BK7503","BK7007","XAO.AU","360.AU"],"gpt_icon":0},{"id":"2527949372","title":"Beginner investor? Here's how I'd invest $1,000 in ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2527949372","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527949372?lang=en_us&edition=fundamental","pubTime":"2025-04-14 08:50","pubTimestamp":1744591800,"startTime":"0","endTime":"0","summary":"Getting started with ASX shares can feel overwhelming — especially with only a small amount to invest. But it is important to know that you don't need to be a financial wizard or have deep pockets to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/14/beginner-investor-heres-how-id-invest-1000-in-asx-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IVV.AU","NDQ.AU","BK7094","PME.AU","FDN","BK4550","BK4585","BK4588"],"gpt_icon":0},{"id":"2526150051","title":"Why this fund manager is all in on Pro Medicus shares and recently increased his bet","url":"https://stock-news.laohu8.com/highlight/detail?id=2526150051","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526150051?lang=en_us&edition=fundamental","pubTime":"2025-04-11 13:33","pubTimestamp":1744349612,"startTime":"0","endTime":"0","summary":"Pro Medicus Ltd  shares have suffered from the recent market volatility, just like many other ASX shares in the last few weeks. One fund manager has seen the decline as a compelling buying opportunity. For readers who don't know, Pro Medicus is a leading healthcare informatics company that provides a full range of medical imaging software and services to hospitals, imaging centres, and healthcare groups. According to reporting by the Australian Financial Review, portfolio manager Robert Miller from Naos Asset Management was on the hunt for good value opportunities after the latest sell-off. Miller, nor anyone, could say what's going to happen in the short term with the ASX stock market, but suggested that it was \"probably safe to say it will be highly volatile\". The fund manager then said he'd rather follow the wisdom of buying good companies at fair prices and holding for the long term. The indiscriminate selling by the market \"can be a wonderful thing\" for patient investors who have ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/11/why-this-fund-manager-is-all-in-on-pro-medicus-shares-and-recently-increased-his-bet/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["PME.AU","BK7094","EBIT"],"gpt_icon":0},{"id":"2526571503","title":"How dollar cost averaging can reduce stress in a volatile market","url":"https://stock-news.laohu8.com/highlight/detail?id=2526571503","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526571503?lang=en_us&edition=fundamental","pubTime":"2025-04-11 08:29","pubTimestamp":1744331379,"startTime":"0","endTime":"0","summary":"There's nothing quite like a market selloff to test an investor's nerves. One minute your portfolio is riding high — the next, red screens and panic headlines are everywhere. But if there's one strategy that can help cut through the noise and bring back a sense of control, it is dollar cost averaging. Instead of trying to time the bottom — something even the pros rarely get right — dollar cost averaging is all about investing a set amount at regular intervals, regardless of where the market is. It smooths out the ups and downs and takes emotion out of the equation. And right now, with high-quality names falling hard but still offering strong long-term potential, it's a strategy that makes more sense than ever. The market is down. But the future isn't broken. Take Pro Medicus Ltd , for example. The health imaging software company is one of the ASX's true long-term winners, with massive global contracts, high margins, and a debt-free balance sheet. Its share price, however, has pulled ba","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/11/how-dollar-cost-averaging-can-reduce-stress-in-a-volatile-market/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["PME.AU","BK4585","FDN","BK4588","BK4550","BK7094","NDQ.AU"],"gpt_icon":0},{"id":"2526547951","title":"What I'd buy before the ASX rebounds: 3 high-conviction share picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2526547951","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526547951?lang=en_us&edition=fundamental","pubTime":"2025-04-11 05:26","pubTimestamp":1744320372,"startTime":"0","endTime":"0","summary":"It is fair to say that the ASX has taken a major hit this month. But here's the thing: markets don't fall forever — and when the rebound comes, it tends to reward those who stayed calm and acted early","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/11/what-id-buy-before-the-asx-rebounds-3-high-conviction-share-picks/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU2237443465.HKD","BK4127","CSL.AU","LU2237443622.USD","IE0034235188.USD","LU2237443382.USD","IE00BSNM7G36.USD","LU2237443895.HKD","BK4504","IE00BFXG1179.USD","PME.AU","BK7155","IE00B19Z3B42.SGD","IE0002270589.USD","BK4588","IE00B19Z3581.USD","LU0251142724.SGD","LU2237438978.USD","BK4552","BK7099","BK4516","LU1868836591.USD","BK4585","BK7510","BK7094","LU1868837136.USD","LU1868836914.USD","BK4533","LU0096364046.USD","GMG.AU","LU0742534661.SGD","LU1791807156.HKD","LU2237443978.SGD","LU2471134523.USD","IE0004086264.USD","LU0048573561.USD","LU2237443549.SGD","IE0004091025.USD","LU1868836757.USD","LU2471134796.USD","BK7501","BK7511","LU2471134879.HKD","LU0106831901.USD","LU0251131958.USD","LU1868837300.USD","LU1668664300.SGD","BK7067","BK7508","LU0061475181.USD"],"gpt_icon":0},{"id":"2526867503","title":"Market Chatter: Pro Medicus Upgraded to \"Overweight\" by Barrenjoey, Reports Australian Financial Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2526867503","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526867503?lang=en_us&edition=fundamental","pubTime":"2025-04-09 14:29","pubTimestamp":1744180191,"startTime":"0","endTime":"0","summary":"Pro Medicus  has been upgraded by Barrenjoey to \"overweight\" after a 40% decline from its February peak, Australian Financial Review reported Tuesday citing Josh Kannourakis from the research firm.The research firm maintained Pro Medicus' price target of AU$275, the report said.The analyst said he now considers the company \"undervalued\" but its valuations continue to be a \"key debate\".He added that a recent rollout of its core platform for medical imaging technology with an unnamed customer has \"proven the company's competitive advantage,\" as cited in the report.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","PME.AU","XAO.AU","XJO.AU"],"gpt_icon":0},{"id":"2526873482","title":"Market selloff creates rare buying window: 3 quality ASX 200 shares I'd buy right now","url":"https://stock-news.laohu8.com/highlight/detail?id=2526873482","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526873482?lang=en_us&edition=fundamental","pubTime":"2025-04-09 08:43","pubTimestamp":1744159380,"startTime":"0","endTime":"0","summary":"The ASX 200 has taken another hit on Wednesday, with the share market dragged lower by global trade tensions and another round of volatility on Wall Street. While that's rattled confidence, experience","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/09/market-selloff-creates-rare-buying-window-3-quality-asx-200-shares-id-buy-right-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4504","LU1668664300.SGD","LU1868836914.USD","LU2471134879.HKD","LU0048573561.USD","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU2237438978.USD","LU0061475181.USD","LU2237443549.SGD","BK7078","LU0742534661.SGD","BK4585","LU0251142724.SGD","LU1868836591.USD","BK4588","LU2471134523.USD","IE00BFXG1179.USD","LU2471134952.CNY","LU2237443978.SGD","IE0004091025.USD","LU1868836757.USD","XRO.AU","LU2471134796.USD","LU2237443895.HKD","IE0004086264.USD","LU1868837136.USD","BK7094","BK4552","BK7016","IE0034235188.USD","LU2750360997.AUD","PME.AU","BK4533","LU0096364046.USD","LU0106831901.USD","LU2237443382.USD","LU2237443465.HKD","IE00B19Z3581.USD","LU2237443622.USD","IE0002270589.USD","LU0251131958.USD","BK4127","LU1868837300.USD","BK4516","BK4550","BK7503","LU2750360641.GBP","ALL.AU","LU1791807156.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PME.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-27","symbol":"PME.AU","amount":0.25,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-02-28","name":"PRO MEDICUS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-21","payableDate":"2025-02-28","currency":"AUD","dateTimestamp":1740574800000,"payDate":"2025-03-21"},{"date":"2025-02-11","symbol":"PME.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739228400000,"name":null,"time":"","dateTimestamp":1739192400000,"actualEps":null},{"date":"2024-09-04","symbol":"PME.AU","amount":0.22,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-09-05","defaultRemindTime":1725408000000,"name":"PRO MEDICUS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-26","payableDate":"2024-09-05","currency":"AUD","dateTimestamp":1725372000000,"payDate":"2024-09-26"},{"date":"2024-08-14","symbol":"PME.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1723593600000,"name":null,"time":"","dateTimestamp":1723557600000,"actualEps":null},{"date":"2024-02-29","symbol":"PME.AU","amount":0.18,"announcedDate":null,"type":"dividend","market":"AU","newRecordDate":"2024-03-01","defaultRemindTime":1709161200000,"name":"Pro Medicus Ltd","recordDate":"2024-03-22","payableDate":"2024-03-01","currency":"AUD","dateTimestamp":1709125200000,"payDate":"2024-03-22"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PME.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-02","value":0.06,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-03-19","value":0.07,"currency":"AUD"},{"executeDate":"2021-09-09","recordDate":"2021-09-10","paymentDate":"2021-10-01","value":0.08,"currency":"AUD"},{"executeDate":"2022-03-03","recordDate":"2022-03-04","paymentDate":"2022-03-25","value":0.1,"currency":"AUD"},{"executeDate":"2022-09-08","recordDate":"2022-09-09","paymentDate":"2022-09-30","value":0.12,"currency":"AUD"}]}}